Efektivitas Suplementasi Vitamin C Terhadap Penurunan Kadar Il-6 Serum dan Aktivitas Penyakit Pasien Lupus Eritematosus Sistemik
DOI:
https://doi.org/10.35790/ecl.v14i1.63617Keywords:
lupus eritematosus sistemik; Mex-SLEDAI; suplementasi vitamin C; interleukin 6Abstract
Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease and its activity is related to interleukin-6 (IL-6) level. Lowering IL-6 levels can help to achieve remission. Vitamin C has antioxidant and immunomodulatory properties that have the potential to lower IL-6 level. However, research on vitamin C in SLE patients, especially in Indonesia, is still very limited. This study aimed to determine the effectiveness of vitamin C supplementation in reducing serum IL-6 levels and disease activity in SLE patients. This was a double-blind randomized controlled trial conducted on 34 patients with mild–moderate SLE at Dr. Mohammad Hoesin General Hospital. Subjects were divided into two groups namely intervention (vitamin C 2 x 500 mg/day) and control (placebo) groups, for eight weeks. Serum IL-6 levels and disease activity scores (Mex-SLEDAI) were measured before and after the intervention. The results showed that the vitamin C group had a significant decrease in serum IL-6 levels compared to placebo group, from a median of 6.46 (3.5–14.4) to 3.5 (3.5–8.36) pg/mL (p=0.001), while in the placebo group decreased from 3.7 (3.5–6.45) to 3.9 (3.5–14) pg/mL (p=0.136). The decrease in Mex-SLEDAI scores was statistically more significant in the vitamin C group compared to the placebo group (p=0.048). In conclusion, vitamin C 2x500 mg/day supplementation for eight weeks effectively reduces serum IL-6 levels and disease activity in mild–moderate SLE patients.
Keywords: systemic lupus erythematosus; MEX-SLEDAI; vitamin C supplementation; interleukin 6
Abstrak: Lupus eritematosus sistemik (LES) merupakan penyakit autoimun kronik yang derajat aktivitasnya berkaitan dengan kadar interleukin-6 (IL-6). Penurunan kadar IL-6 dapat membantu dalam mencapai remisi. Vitamin C memiliki sifat antioksidan dan imunomodulator yang berpotensi menurunkan kadar IL-6, namun, penelitian mengenai vitamin C pada pasien LES khususnya di Indonesia masih sangat terbatas. Penelitian ini bertujuan untuk mengetahui efektivitas suplementasi vitamin C terhadap penurunan kadar IL-6 serum dan aktivitas penyakit pada pasien LES. Penelitian ini menggunakan uji klinis acak tersamar ganda dilakukan pada 34 pasien LES derajat ringan–sedang di RSUP Dr. Mohammad Hoesin. Subjek dibagi menjadi dua kelompok: intervensi (vitamin C 2x500 mg/hari) dan kontrol (plasebo), selama delapan minggu. Kadar IL-6 serum dan skor aktivitas penyakit (Mex-SLEDAI) diukur sebelum dan sesudah intervensi. Hasil penelitian mendapatkan bahwa kelompok vitamin C menunjukkan penurunan bermakna kadar IL-6 serum dibandingkan placebo dari median 6,46 (3,5–14,4) menjadi 3,5 (3,5–8,36) pg/mL (p=0,001), sedangkan kelompok plasebo dari 3,7 (3,5–6,45) menjadi 3,9 (3,5–14) pg/mL (p=0,136). Penurunan skor Mex-SLEDAI secara statistik lebih bermakna pada kelompok vitamin C dibandingkan plasebo (p=0,048). Simpulan penelitian ini ialah suplementasi vitamin C 2x500 mg/hari selama delapan minggu efektif menurunkan kadar IL-6 serum dan aktivitas penyakit lupus eritematosus sistemik derajat ringan–sedang.
Kata kunci: lupus eritematosus sistemik; Mex-SLEDAI; suplementasi vitamin C; interleukin 6
References
1. Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14(10):e30330. Doi: 10.7759/cureus.30330
2. Ding J, Su S, You T, Xia T, Lin X, Chen Z, et al. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. Clinics. 2020;75:e1801. Doi: https://doi.org/10.6061/ clinics/2020/e1801
3. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med. 2017;23(7):615-35. Doi: 10.1016/j.molmed. 2017.05.006
4. Umare V, Pradhan V, Nadkar M, Rajadhyaksha A, Patwardhan M, Ghosh KK, et al. Effect of proinflammatory cytokines (IL-6, TNF-α, and IL-1β) on clinical manifestations in Indian SLE patients. Mediators Inflamm. 2014;2014:385297. Doi: 10.1155/2014/385297
5. Thanadetsuntorn C, Ngamjanyaporn P, Setthaudom C, Hodge K, Saengpiya N, Pisitkun P. The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus. Sci Rep. 2018;8(1):2620. Doi: 10.1038/s41598-018-20947-4.
6. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XYR. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119(3):296-305. Doi: 10.1111/j.1365-2567.2006.02433.x
7. Idborg H, Oke V. Cytokines as Biomarkers in systemic lupus erythematosus: value for diagnosis and drug therapy. Int J Mol Sci. 2021;22(21):11327. Doi: 10.3390/ijms222111327.
8. Jin S, Yu C, Yu B. Changes of serum IL-6, IL-10 and TNF-α levels in patients with systemic lupus erythematosus and their clinical value. Am J Transl Res. 2021;13(4):2867-74. Available from: pubmed.ncbi. nlm.nih.gov/34017450/
9. Emamikia S, Oon S, Gomez A, Lindblom J, Borg A, Enman Y, et al. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022;61(12):4752-62. Doi: 10.1093/rheumatology/keac185
10. Medina-Quiñones CV, Ramos-Merino L, Ruiz-Sada P, Isenberg D. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 2016l;68(7):981–7. Doi: 10.1002/acr.22774
11. Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. 2017;76(3):547–53. Ann Rheum Dis. 2017;76(3):547-53. Doi: 10.1136/annrheumdis-2016-209489.
12. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211. Doi: 10.3390/nu9111211.
13. Gholizadeh M, Ghafour Saeedy SA, Abdi A, Khademi F, Lorian K, Clark CCT, et al. Vitamin C reduces interleukin-6 plasma concentration: a systematic review and meta-analysis of randomized clinical trials. Clin Nutr Open Sci. 2021;40:1–14. Doi: 10.1016/j.nutos.2021.09.003
14. Ellulu MS, Rahmat A, Patimah I, Khaza’Ai H, Abed Y. Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: a randomized controlled trial. Drug Des Devel Ther. 2015;9:3405-12. Doi: 10.2147/DDDT.S83144
15. Tam LS, Li EK, Leung VYFF, Griffith JF, Benzie IFFF, Lim PL, et al. Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study. J Rheumatol. 2005;32(2):275–82. Available from: https:// pubmed.ncbi. nlm.nih.gov/15693087/
16. Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol. 2012;2012:604892. Doi: 10.1155/2012/60489
17. Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015;76(2):280–7. Doi: http://dx.doi.org/10.1016/j.cyto.2015.05.007
18. Minami Y, Sasaki T, Arai Y, Kurisu Y, Hisamichi S. Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. J Rheumatol. 2003;30(4):747-54. Available from: https:// pubmed.ncbi.nlm.nih.gov/12672194/
19. Mussa A, Afolabi HA, Syed NH, Talib M, Murtadha AH, Hajissa K, et al. The NF-κB transcriptional network is a high-dose vitamin C-targetable vulnerability in breast cancer. Biomedicines. 2023;11(4):1060. Doi: https://doi.org/10.3390/biomedicines11041060
20. Primavera D, Carta MG, Romano F, Sancassiani F, Chessa E, Floris A, et al. Quality of life in systemic lupus erythematosus and other chronic diseases: highlighting the amplified impact of depressive episodes. Healthcare. 2024;12(2):233. Doi: https://doi.org/10.3390/healthcare12020233
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ady F. Saragih, Nova Kurniati, Theodorus Theodorus, Eddy M. Salim, Yuniza Yuniza
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
